Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase NA 5Phase 1 4Phase 4 1Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 4Gynecologic 3Breast 2Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Anemia, Refractory, with Excess of Blasts 62Leukemia, Myeloid, Acute 51Myelodysplastic Syndromes 39Leukemia 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Leukemia, Myelomonocytic, Chronic 34Leukemia, Lymphocytic, Chronic, B-Cell 26Blast Crisis 23Myeloproliferative Disorders 20Congenital Abnormalities 20Multiple Myeloma 17Anemia, Refractory 15Myelodysplastic-Myeloproliferative Diseases 14Hodgkin Disease 14Anemia 14Primary Myelofibrosis 13Lymphoma 13Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 13Lymphoma, Non-Hodgkin 12Leukemia, Myeloid, Chronic-Phase 12Thrombocytopenia 11Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 11Leukemia, Myeloid, Accelerated Phase 11Lymphoma, Large-Cell, Immunoblastic 10Lymphoma, Large B-Cell, Diffuse 10Hematologic Neoplasms 10Burkitt Lymphoma 10Lymphoma, Follicular 9Leukemia, Prolymphocytic 8

Interventions

olaparib 2talazoparib 1Carboplatin 1ABT-767 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Fanconi Anemia, Complementation Group D1 × Classical hematology × Clear all
NCT00516373 2024-02-22

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

AstraZeneca

Phase 1 Completed
98 enrolled
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02418624 2019-01-16

REVIVAL

The Netherlands Cancer Institute

Phase 1 Completed
25 enrolled
BreastClassical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Ovarian Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

Phase 1 Completed
113 enrolled 39 charts
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

NCT01339650 2018-01-02

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

AbbVie

Phase 1 Completed
93 enrolled
Classical hematology

Fanconi Anemia, Complementation Group D1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡